Synairgen plc

For #media #investors:   This morning we published our interim statement of unaudited results for the six months ended 30 June 2024.   Read the statement on our website: https://lnkd.in/e8Ty7MUw   #SNG

For #media #investors: Richard sat down with Proactive to provide some commentary on today’s results and the rationale behind its planned trial in mechanically ventilated patients. Watch the full interview here: https://lnkd.in/e_TteV4a

For #media #investors:   This morning we published our preliminary statement of audited results for the year ended 31 December 2023 and our Annual Report.   Read the results statement here: https://lnkd.in/eqCyecgD   Read the Annual Report here: https://lnkd.in/eHHTW7RA #SNG

For #Media #Investors Data from our two-part Phase 2 SG015 trial exploring the potential of SNG001 (inhaled interferon beta) as a treatment for exacerbations of COPD caused by viral respiratory infections has been published in Respiratory Research, a Springer Nature Group publication. Read more on the data: https://lnkd.in/d-5rNxmm #COPD #SNG #Publication

For #Attendees #Media Our Chief Scientific Officer Phillip Monk will be presenting a poster at the American Thoracic Society (ATS) conference on Monday, 20 May in San Diego. The poster presentation, titled ‘Analysis of Baseline Factors Associated With Poor Clinical Outcome in a Phase 3 Trial in Patients Hospitalized Due to COVID-19’ will be taking place at 9:15 AM PT in the San Diego Convention Center, Area H (Hall H, Ground Level). #ATS2024 #SNG #PosterPresentation

For #Media #Investors   Novel therapeutics to prevent progression to severe COVID-19 remains a critical need so we are pleased to note the presentation of our previously shared in vitro data on SNG001’s effectiveness against various COVID-19 variants at the Microbiology Society Annual Conference earlier this week by UK Health Security Agency’s (UKHSA) Julia Tree. The presentation by the UKHSA underlines the potential for SNG001 for future pandemic preparedness. Further details on the abstract (A368) can be found here: https://lnkd.in/dXHqkfms   #SNG

For #Media #Investors Encouraging data from our SG015 randomised, placebo-controlled Phase 2 clinical study in COPD patients have been published in the Oxford Academic Journal’s Open Forum Infectious Diseases. With no approved broad-spectrum antiviral therapeutic options to treat patients suffering from respiratory viral illness, there is a strong unmet clinical need. Read the publication: https://lnkd.in/gHce5EQg #Publication #SNG